At the EASL Congress 2024, Eli Lilly and Company presented positive results from the Phase II clinical trial, SYNERGY-NASH, of their tirzepatide for treating patients with biopsy-proven MASH with stage 2 or 3 fibrosis
Food and Drug Administration (FDA) for chronic weight management along with diet and exercise in adults with obesity or overweight with at least one other weight-related medical condition and obstructive sleep apnea (OSA) for adults with obesity
Our weight loss program in Missouri City, Texas uses GLP-1 medications including Ozempic, Mounjaro, Wegovy, Zepbound, and more to help patients lose weight and reach their goals under the guidance of a licensed provider
Photo by Innerbody Research This serum comes in a 30mL airless pump bottle, meaning you wont have to worry about dealing with a dropper like with our picks from The Ordinary and NIOD
That gap is now publicly visible
Cost and Access Barriers: These medications are expensive, and insurance coverage for weight loss is often limited, posing significant practical challenges
